Načítá se...
Trials in type 1 diabetes: Antigen-specific therapies
Type 1 diabetes (T1D) results from an aberrant immunological response against the insulin-producing beta cells in the islets of the pancreas. The ideal therapy would restore immune balance in a safe and lasting fashion, stopping the process of beta cell decay. The efficacy of immune suppressive agen...
Uloženo v:
| Vydáno v: | Clin Immunol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5777514/ https://ncbi.nlm.nih.gov/pubmed/23490422 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clim.2013.02.002 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|